In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various…
Browsing: CAR T-cell
Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in…
CAR T-cell: Advances in Adoptive Therapies for Targeting Heterogeneity in mCRPC Lupita Lopez By Lupita Lopez, BS Ph.D. candidate at…
How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD…
2023 ASH BCMA & Multiple Myeloma Updates with Slides by: Lisa Lee, MD – Assistant Professor — Division of Hematology-Oncology, Department…
Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell lymphoma LBCL Lisocabtagene Maraleucel…